CytomX Therapeutics CTMX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total External Costs by Product | ||||||
| Cx801Ifnalpha2B | $344K-29.5% | $319K-28.3% | $369K-19.1% | $452K-25.3% | $488K-51.2% | |
| Cx904Egfrxcd3 | $241K-78.3% | —— | $150K-94.4% | -$550K-128% | $1.11M-8.3% | |
| Other Wholly Owned And Partnered Programs | $143K-64.0% | $565K-61.8% | $462K-41.0% | $498K-69.4% | $397K-87.5% | |
| Varseta-M Ep CAM | $7.81M+83.0% | —— | —— | —— | $4.27M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does CytomX Therapeutics break its business down?
- CytomX Therapeutics (CTMX) reports total external costs by product across 5 parts — Cx801Ifnalpha2B, Cx904Egfrxcd3, Other Wholly Owned And Partnered Programs, Varseta-M Ep CAM and Varseta-M. Each is extracted from the segment footnotes and tracked over time.
- Where does CytomX Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in CytomX Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
